Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLOZAPINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN PATIENTS WITH SCHIZOPHRENIA WHO ARE UNRESPONSIVE TO OR INTOLERANT OF CLASSICAL ANTIPSYCHOTIC AGENTS
Autore:
WAGSTAFF AJ; BRYSON HM;
Indirizzi:
ADIS INT LTD,41 CENTORIAN DR,PRIVATE BAG 65901 AUCKLAND 10 NEW ZEALAND
Titolo Testata:
CNS DRUGS
fascicolo: 5, volume: 4, anno: 1995,
pagine: 370 - 400
SICI:
1172-7047(1995)4:5<370:C-AROI>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC MALIGNANT SYNDROME; COLONY-STIMULATING FACTOR; OBSESSIVE-COMPULSIVE SYMPTOMS; TREATMENT-REFRACTORY SCHIZOPHRENIA; PERFORMANCE LIQUID-CHROMATOGRAPHY; MULTIPLE-DOSE PHARMACOKINETICS; IDIOPATHIC PARKINSONS-DISEASE; DOPAMINE D4 RECEPTORS; INDUCED AGRANULOCYTOSIS; TARDIVE-DYSKINESIA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
402
Recensione:
Indirizzi per estratti:
Citazione:
A.J. Wagstaff e H.M. Bryson, "CLOZAPINE - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN PATIENTS WITH SCHIZOPHRENIA WHO ARE UNRESPONSIVE TO OR INTOLERANT OF CLASSICAL ANTIPSYCHOTIC AGENTS", CNS DRUGS, 4(5), 1995, pp. 370-400

Abstract

Clozapine is an atypical antipsychotic agent whose mode of action is thought to pertain to its interactions with dopamine and serotonin (5-hydroxytryptamine) neurotransmitter systems. Clinical efficacy may be related to plasma clozapine concentrations. Response rates have variedwidely on short term therapy (30 to 100%); during longer term treatment, 60% of patients unresponsive to or intolerant of previous antipsychotic therapy responded to clozapine. Significant improvement in both positive and negative psychotic symptoms, quality of life, social functioning and suicidality has been demonstrated Clozapine has demonstrated superior efficacy to that of chlorpromazine, haloperidol and fluphenazine in treatment-resistant patients, and improvements were maintained with long term treatment. Economic savings may be realised after the first 1 to 2 years of clozapine therapy. Extrapyramidal symptoms occur less frequently and appear to be less severe in patients receiving clozapine than in those receiving classical antipsychotic agents. The incidence of tardive dyskinesia and neuroleptic malignant syndrome is very low. Agranulocytosis appears to occur in about 0.8% of clozapine recipients, and the incidence has been reported to decrease after the first year of therapy. Regular blood monitoring is mandatory. More frequent adverse events associated with clozapine include tachycardia, sedation, hypersalivation and orthostatic hypotension. With regular blood monitoring, clozapine is the drug of choice for patients with schizophrenia who are unresponsive to or intolerant of previous antipsychotic therapy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 00:59:22